A new discovery by researchers from Ben-Gurion University of the Negev (BGU) and its affiliated Soroka University Medical Center shows that medical cannabis may reduce blood pressure in older adults.
The study, published in the European Journal of Internal Medicine, is the first of its kind to focus on the effect of cannabis on blood pressure, heart rate and metabolic parameters in adults 60 and above with hypertension.
“Older adults are the fastest growing group of medical cannabis users, yet evidence on cardiovascular safety for this population is scarce,” says Dr. Ran Abuhasira of the BGU Faculty of Health Sciences, one of Israel’s leading medical faculties, and the BGU-Soroka Cannabis Clinical Research Institute. “This study is part of our ongoing effort to provide clinical research on the actual physiological effects of cannabis over time.”
Patients were evaluated using 24-hour ambulatory blood pressure monitoring, ECG, blood tests, and body measurements — both before and three months after initiating cannabis therapy.
In the study, researchers found a significant reduction in 24-hour systolic and diastolic blood pressure values, with the lowest point occurring three hours after ingesting cannabis either orally via oil extracts or by smoking. Patients showed reductions in blood pressure in both daytime and nighttime, with more significant changes at night.
The BGU researchers theorize that the relief from pain, the indication for prescription cannabis in most patients, may also have contributed to a reduction in blood pressure.
“Cannabis research is in its early stages and BGU is at the forefront of evaluating clinical use based on scientific studies,” says Doug Seserman, chief executive officer of American Associates, Ben-Gurion University of the Negev. “This new study is one of several that has been published recently by BGU on the medicinal benefits of cannabis.”
Reference: “Cannabis is associated with blood pressure reduction in older adults – A 24-hours ambulatory blood pressure monitoring study” by Ran Abuhasira, Yosef S. Haviv, Merav Leiba, Adi Leiba, Larisa Ryvo and Victor Novack, 20 January 2021, European Journal of Internal Medicine.
Additional researchers who participated in the study include: Prof. Victor Novack, director of the BGU-Soroka Cannabis Clinical Research Institute and BGU-Soroka Clinical Research Center and Research Authority; Prof. Yosef Haviv, director of the Department of Nephrology at Soroka; Prof. Merav Leiba, Prof. Adi Leiba and Dr. Larisa Ryvo of the Assuta Ashdod Academic Medical Center.